



(Modified) PTO/SB/08A-B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031

<b>Substitute for form 1449A-B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Complete if Known</b>	
	Application Number	09/724,869
	Filing Date	November 28, 2000
	First Named Inventor	Juha Punnonen
	Group Art Unit	1639
	Examiner Name	Teresa Wessendorf
	Attorney Docket Number	0155.130US

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
TW	1	6,368,861		Cramer et al.	04-23-2002	
	2	6,406,855		Patten et al.	06-18-2002	
V	3	6,613,514		Patten et al.	09-02-2003	

FOREIGN PATENT DOCUMENTS							
Exami ner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office	Number	Kind Code (if known)			

Examiner Signature	T.D. J	Date Considered	7/16/07
-----------------------	--------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)	Complete if Known	
	Application Number	09/724,869
	Filing Date	November 28, 2000
	First Named Inventor	Juha Punnonen
	Group Art Unit	1639
	Examiner Name	Teresa Wessendorf
Attorney Docket Number		0155.130US

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages, or Relevant Figures Appear
		Number	Kind Code (if known)			
SW	1	6,376,246		Cramer et al.	04-09-2002	

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office	Number	Kind Code (if known)			
SW	2	WO	91/19818	A1	Affymax Technologies N.V.	12-26-1991	
	3	WO	92/01047	A1	Cambridge Antibody Technology Limited	01-23-1992	
	4	WO	92/18619	A1	The Scripps Research Institute	10-29-1992	
	5	WO	94/01567	A1	Unilever PLC	01-20-1994	
	6	WO	94/18330	A1	Unilever PLC	08-18-1994	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
SW	7	Aggarwal & Gutterman eds., HUMAN CYTOKINES: HANDBOOK FOR BASIC AND CLINICAL RESEARCH, Vol. II (1996) (Table of Contents for Vols. 1 & II)
	8	Alcami et al., "A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection," <i>Cell</i> 71(1):153-67 (1992)
	9	Apostolopoulos et al., "Breast cancer immunotherapy: Current status and future prospects," <i>Immunol. and Cell. Biol.</i> 74:457-64 (1996)
	10	Atamas et al., "An alternative splice variant of human IL-4, IL-4 delta 2, inhibits IL-4-stimulated T cell proliferation," <i>J. Immunol.</i> 156(2):435-41 (1996)
	11	Aversa et al., "SLAM and its role in T cell activation and Th cell responses." <i>Immunol. Cell Biol.</i> 75(2):202-5 (1997)
	12	Bach et al., "The IFN gamma receptor: a paradigm for cytokine receptor signaling," <i>Annu. Rev. Immunol.</i> 15:563-91 (1997)
	13	Baggiolini et al., "Human Cytokines: An Update," <i>Annu. Rev. Immunol.</i> 15:675-705 (1997)
	14	Balbas et al., "Design and Construction of Expression Plasmid Vectors in Escherichia coli," in METHODS IN ENZYMOLOGY: GENE EXPRESSION TECHNOLOGY 185:14-37 (David V. Goeddel ed., Acad. Press, Inc., 1990)
	15	Basham et al., "Synergistic antitumor activity with IFN and monoclonal anti-idiotype for murine B cell lymphoma. Mechanism of action," <i>J. Immunol.</i> 141(8):2855-60 (1988)
	16	Beck et al., "Analysis of Multiple Plasmodium falciparum Infections in Tanzanian Children during the Phase II Trial of Malaria Vaccine SPf66," <i>J. Inf. Disease</i> 175:921-26 (1997)

17	Becket <i>et al.</i> , "Characterization of a Prostate Carcinoma Mucin-Like Antigen (PMA)," <i>Int. J. Cancer</i> 62:703-10 (1995)
18	Bramson <i>et al.</i> , "Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: in vitro and in vivo production of biologically active interleukin-12," <i>Hum. Gene Ther.</i> 7(3):333-42 (1996)
19	Brusselle <i>et al.</i> , "Role of IFN- $\gamma$ in the Inhibition of Allergic Airway Inflammation Caused by IL-12," <i>Am. J. Respir. Cell Mol. Biol.</i> 17:767-71 (1997)
20	Censini <i>et al.</i> , "cag, a pathogenicity island of <i>Helicobacter pylori</i> , encodes type I-specific and disease-associated virulence factors," <i>PNAS</i> 93:14648-53 (1996)
21	Chen <i>et al.</i> , "Discontinuous epitopes of hepatitis B surface antigen derived from a filamentous phage peptide library," <i>PNAS USA</i> 93(5):1997-2001 (1996)
22	Chow <i>et al.</i> , "Improvement of Hepatitis B Virus DNA Vaccines by Plasmids Coexpressing Hepatitis B Surface Antigen and Interleukin-2," <i>J. Virol.</i> 71(1):169-78 (1997)
23	Ciernik <i>et al.</i> , "Induction of Cytotoxic T Lymphocytes and Antitumor Immunity with DNA Vaccines Expressing Single T Cell Epitopes," <i>J. Immunol.</i> 156:2369-75 (1996)
24	Cohen <i>et al.</i> , "Host factors in the pathogenesis of HIV disease," <i>Immunol. Rev.</i> 159:31-48 (1997)
25	Cortese <i>et al.</i> , "Selection of biologically active peptides by phage display of random peptide libraries," <i>Curr. Opin. Biotechnol.</i> 7(6):616-21 (1996)
26	Curtis <i>et al.</i> , "Recombinant Soluble Interleukin-11 (IL-11) Receptor alpha Chain Can Act as an IL-11 Antagonist," <i>Blood</i> 90(11):4403-12 (1997)
27	Cwirla <i>et al.</i> , "Peptide Agonist of the Thrombopoietin Receptor as Potent as the Natural Cytokine," <i>Science</i> 276:1696-9 (1997)
28	Dagan <i>et al.</i> , "High level expression and production of recombinant human Interleukin analogs," <i>Protein Expr. Purif.</i> 3(4):290-4 (1992)
29	Devos <i>et al.</i> , "Interleukin-5 and its receptor: a drug target for eosinophilia associated with chronic allergic disease," <i>J. Leukoc. Biol.</i> 57(6):813-19 (1995)
30	De Vries <i>et al.</i> , "Novel fundamental approaches to intervening in IgE-mediated allergic diseases," <i>J. Invest. Dermatol.</i> 102(2):141-4 (1994)
31	De Vries <i>et al.</i> , <i>Interleukin-4 and Interleukin-13</i> , Chap. 8, in <i>CYTOKINE REGULATION OF HUMORAL IMMUNITY: BASIC AND CLINICAL ASPECTS</i> 195-215 (C. M. Snapper, West Sussex, UK, John Wiley and Sons, 1996)
32	De Vries <i>et al.</i> , "Modulation of the human IgE response," <i>Eur. Respir. J. Suppl.</i> 22:58s-62s (1996)
33	De Waal Malefyt <i>et al.</i> , "A Novel Cytokine Belonging to the IL-10 Gene Family Affects Human Monocytes and T Cells," Abstract, 13th European Immunology Meeting, Amsterdam, Netherlands, June 1997, <i>Immunol. Letters</i> 56(1):211 (May 1997)
34	Donnelly <i>et al.</i> , "DNA Vaccines," <i>Annu. Rev. Immunol.</i> 15:617-48 (1997)
35	Dudler <i>et al.</i> , "A Link Between Catalytic Activity, IgE-Independent Mast Cell Activation and Allergenicity of Bee Venom Phospholipase A <sub>2</sub> ," <i>J. Immunol.</i> 155(5):2605-13 (1995)
36	Eckhart <i>et al.</i> , "Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus," <i>J. Gen. Virol.</i> 77 (9):2001-8 (1996)
Examiner Signature	Date Considered
J. D. J.	7/16/07

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

✓	37	Fomsgaard <i>et al.</i> , "Improved humoral and cellular immune response against the gp120 V3 loop of HIV-1 following genetic immunization with a chimeric DNA vaccine encoding the V3 inserted in the hepatitis B surface antigen," <i>Scand. J. Immunol.</i> 47(4):289-95 (1998)	
	38	Foy <i>et al.</i> , "Immune regulation by CD40 and its ligand GP39," <i>Annu. Rev. Immunol.</i> 14:591-617 (1996)	
	39	Fromm <i>et al.</i> , "Expression of genes transferred into monocot and dicot plant cells by electroporation," <i>PNAS USA</i> 82(17):5824-28 (1985)	
	40	Gauchat <i>et al.</i> , "Regulation of human IgE synthesis: the role of CD4+ and CD8+ T-cells and the inhibitory effects of interferon-alpha," <i>Eur. Respir. J. Suppl.</i> 13:31s-38s (1991)	
	41	Goff <i>et al.</i> , "Laboratory Methods: Efficient Saturation Mutagenesis of a Pentapeptide Coding Sequence Using Mixed Oligonucleotides," <i>DNA</i> 6(4):381-388 (1987)	
	42	Greenfeder <i>et al.</i> , "Insertion of a Structural Domain of Interleukin (IL)-1B Confers Agonist Activity to the IL-1 Receptor Antagonist," <i>J. Biol. Chem.</i> 270:22460-6 (1995)	
	43	Grewal <i>et al.</i> , "The CD40-CD154 system in anti-infective host defense," <i>Curr. Opin. Immunol.</i> 9(4):491-7 (1997)	
✓	44	Grunig <i>et al.</i> , "Interleukin-10 is a natural suppressor of cytokine production and inflammation in a murine model of allergic bronchopulmonary aspergillosis," <i>J. Exp. Med.</i> 185(6):1089-99 (1997)	
	45	Hannum <i>et al.</i> , "Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor," <i>Nature</i> 343:336-40 (1990)	
	46	Hathcock <i>et al.</i> , "Comparative Analysis of B7-1 and B7-2 Costimulatory Ligands: Expression and Function," <i>J. Exptl. Med.</i> 180:631-40 (1994)	
	47	Herz <i>et al.</i> , "Molecular approaches to receptors as targets for drug discovery," <i>J. Recept. Signal Transduct. Res.</i> 17(5):671-776 (1997)	
	48	Herzenberg <i>et al.</i> eds., WEIR'S HANDBOOK OF EXPERIMENTAL IMMUNOLOGY (5 <sup>th</sup> ed. 1996) (index and first pages of Chaps. 220, 226, 227)	
✓	49	Hess <i>et al.</i> , "Superior efficacy of secreted over somatic antigen display in recombinant <i>Salmonella</i> vaccine induced protection against listeriosis," <i>PNAS</i> 93:1458-63 (1996)	
	50	Hill <i>et al.</i> , "Mutagenesis with Degenerate Oligonucleotides: An Efficient Method for Saturating a Defined DNA Region with Base Pair Substitutions," in METHODS IN ENZYMOLOGY: RECOMBINANT DNA 155:558-568 (Ray Wu ed., Acad. Press, Inc., 1987)	
	51	Horuk, "Molecular properties of the chemokine receptor family," <i>TIPS</i> 15:159-165 (1994)	
	52	Horwitz <i>et al.</i> , "Saturation Mutagenesis Using Mixed Oligonucleotides and M13 Templates Containing Uracil," in METHODS IN ENZYMOLOGY: GENE EXPRESSION TECHNOLOGY 185:599-611 (David V. Goeddel ed., Acad. Press, Inc. 1990)	
	53	Ihle <i>et al.</i> , "Signaling through the hematopoietic cytokine receptors," <i>Annu. Rev. Immunol.</i> 13:369-98 (1995)	
✓	54	Kaufman, "Vectors Used for Expression in Mammalian Cells," in METHODS IN ENZYMOLOGY: GENE EXPRESSION TECHNOLOGY 185:487-511 (David V. Goeddel ed., Acad. Press, Inc., 1990)	
	55	Kay <i>et al.</i> , eds., PHAGE DISPLAY OF PEPTIDES AND PROTEINS: A LABORATORY MANUAL (Acad. Press, Inc., 1996) (first page of Chap. 5)	
✓	56	Krieger <i>et al.</i> , "Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP)," <i>Annu. Rev. Biochem.</i> 63:601-	
Examiner Signature		Date Considered	
T. O. J.		7/16/07	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		37 (1994)	
TW	57	Kroemer <i>et al.</i> , "Immunoregulation by cytokines," <i>Crit. Rev. Immunol.</i> 13(2):163-91 (1993)	
	58	Laberge <i>et al.</i> , "Secretion of IL-16 (Lymphocyte Chemoattractant Factor) from Serotonin-Stimulated CD8 <sup>+</sup> T Cells In Vivo," <i>J. Immunol.</i> 156(1):310-5 (1996)	
	59	Le Borgne <i>et al.</i> , "In Vivo Induction of Specific Cytotoxic T Lymphocytes in Mice and Rhesus Macaques Immunized with DNA Vector Encoding an HIV Epitope Fused with Hepatitis B Surface Antigen," <i>Virology</i> 240:304-15 (1998)	
	60	Le Grice, "Regulated Promoter for High-Level Expression of Heterologous Genes for <i>Bacillus subtilis</i> ," in METHODS IN ENZYMOLOGY: GENE EXPRESSION TECHNOLOGY 185:201-15 (David V. Goeddel ed., Acad. Press, Inc., 1990)	
	61	Levinson, "Expression of Heterologous Genes in Mammalian Cells," in METHODS IN ENZYMOLOGY: GENE EXPRESSION TECHNOLOGY 185:485-87 (David V. Goeddel ed., Acad. Press, Inc., 1990)	
	62	Livnah <i>et al.</i> , "Functional Mimicry of a Protein Hormone by a Peptide Agonist: The EPO Receptor Complex at 2.8," <i>Science</i> 273:464-71 (1996)	
	63	Ma <i>et al.</i> , "Antibody production and engineering in plants," <i>Ann. NY Acad. Sci.</i> 792:72-81 (1996)	
	64	Mattion <i>et al.</i> , "Characterization of recombinant polioviruses expressing regions of rotavirus VP4, hepatitis B surface antigen, and herpes simplex virus type 2 glycoprotein D," <i>J. Virol.</i> 69:5132-37 (1995)	
	65	McLafferty <i>et al.</i> , "M13 bacteriophage displaying disulfide-constrained microproteins," <i>Gene</i> 128(1):29-36 (1993)	
	66	Miele, "Plants as bioreactors for biopharmaceuticals: regulatory considerations," <i>Trends Biotechnol.</i> 15(2):45-50 (1997)	
	67	Mosmann <i>et al.</i> , "Heterogeneity of Cytokine Secretion Patterns and Functions of Helper T cells," <i>Adv. Immunol.</i> 46:111-147 (1989)	
	68	Murray <i>et al.</i> , "Saturation mutagenesis of a major histocompatibility complex protein domain: Identification of a single conserved amino acid important for allorecognition," <i>PNAS USA</i> 85:3535-39 (1988)	
	69	Noguchi <i>et al.</i> , "IgE responsiveness to <i>Dermatophagoides farinae</i> in young asthmatic children: IgE binding study using recombinant allergens of Der f1, Der f2 and mutant proteins of Der f2," <i>Int. Arch. Allergy Immunol.</i> 110(4):380-7 (1996)	
	70	Ostermeier <i>et al.</i> , "A combinatorial approach to hybrid enzymes independent of DNA homology," <i>Nature</i> 391:1205-09 (1999)	
	71	Ostermeier <i>et al.</i> , "Combinatorial protein engineering by incremental truncation," <i>PNAS USA</i> 96:3562-67 (1999)	
	72	Parronchi <i>et al.</i> , "IL-4 and IFN (alpha and gamma) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones," <i>J. Immunol.</i> 149(9):2977-83 (1992)	
	73	Paul, <i>The Immune System: An Introduction</i> , Chap. 1, pp. 1-20 in FUNDAMENTAL IMMUNOLOGY (W. E. Paul. New York, Raven Press, 1993)	
	74	Porcelli, "The CD1 family: a third lineage of antigen-presenting molecules," <i>Adv. Immunol.</i> 59:1-98 (1995)	
Examiner Signature	T. D. J		Date Considered 7/16/07

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<input checked="" type="checkbox"/>	75	Pumpens <i>et al.</i> , "Hepatitis B virus core particles as epitope carriers," <i>Intervirology</i> 38(1-2):63-74 (1995)	
<input type="checkbox"/>	76	Quarantino <i>et al.</i> , "Similar antigenic surfaces, rather than sequence homology dictate T-cell epitope molecular mimicry," <i>PNAS USA</i> 92:10398-402 (1995)	
<input type="checkbox"/>	77	Randhawa <i>et al.</i> , "In vitro culture of B-lymphocytes derived from Epstein-Barr-virus-associated posttransplant lymphoproliferative disease: cytokine production and effect of interferon-alpha," <i>In Vitro Cell Dev. Biol. Anim.</i> 33(10):803-08 (1997)	
<input type="checkbox"/>	78	Sambrook <i>et al.</i> , MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Laboratory Press, New York (2d ed. 1989), Vol. I, pp. 1.53-1.59	
<input type="checkbox"/>	79	Sambrook <i>et al.</i> , MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Laboratory Press, New York (2d ed. 1989), Vol. II, pp. 15.51-15.113	
<input type="checkbox"/>	80	Schrijver <i>et al.</i> , "Comparison of DNA-application methods to reduce BRSV shedding in cattle," <i>Vaccine</i> 16(2-3):130-4 (1998)	
<input type="checkbox"/>	81	Simmons <i>et al.</i> , "Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist," <i>Science</i> 276:276-9 (1997)	
<input type="checkbox"/>	82	Stern <i>et al.</i> , Chap. 4, <i>Interleukin-12</i> , in HUMAN CYTOKINES: HANDBOOK FOR BASIC AND CLINICAL RESEARCH 74-96 (Aggarwal & Guterman eds., 1996)	
<input type="checkbox"/>	83	Tan <i>et al.</i> , "Characterization of IL-10 Receptors on Human and Mouse Cells," <i>J. Biol. Chem.</i> 268(28):21053-59 (1993)	
<input type="checkbox"/>	84	Thomas <i>et al.</i> , "Potent interleukin 3 receptor agonist with selectively enhanced hematopoietic activity relative to recombinant human interleukin 3," <i>PNAS USA</i> 92:3779-83 (1995)	
<input type="checkbox"/>	85	Tuite, "Strategies for the genetic manipulation of <i>Saccharomyces cerevisiae</i> ," <i>Crit. Rev. Biotechnol.</i> 12(1-2):157-88 (1992)	
<input type="checkbox"/>	86	Udagawa <i>et al.</i> , "Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation," <i>J. Exp. Med.</i> 185(6):1005-12 (1997)	
<input type="checkbox"/>	87	Ulrich <i>et al.</i> , "Chimeric HBV core particles carrying a defined segment of Puumala hantavirus nucleocapsid protein evoke protective immunity in an animal model," <i>Vaccine</i> 16(2-3):272-80 (1998)	
<input type="checkbox"/>	88	Villbrandt <i>et al.</i> , "Investigations of the thermostability and function of truncated <i>Thermus aquaticus</i> DNA polymerase fragments," <i>Protein Eng'g</i> 10(11):1281-88 (1997)	
<input type="checkbox"/>	89	Weiner <i>et al.</i> , "Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization," <i>PNAS USA</i> 94:10833-7 (1997)	
<input type="checkbox"/>	90	Yao <i>et al.</i> , "Human IL-17: A Novel Cytokine Derived from T Cells," <i>J. Immunol.</i> 155(12):5483-86 (1995)	
<input type="checkbox"/>	91	York <i>et al.</i> , "Antigen processing and presentation by the class I major histocompatibility complex," <i>Annu. Rev. Immunol.</i> 14:369-96 (1996)	
<input type="checkbox"/>	92	Yoshie <i>et al.</i> , "Novel lymphocyte-specific CC chemokines and their receptors," <i>J. Leukocyte Biol.</i> 62(5):634-44 (1997)	
<input checked="" type="checkbox"/>	93	Zaremba <i>et al.</i> , "Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen," <i>Cancer Res.</i> 57(20):4570-77 (1997)	

Examiner Signature	J. D. J	Date Considered	7/16/07
-----------------------	---------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



<b>Substitute for form 1449A-B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Complete if Known</b>	
	Application Number	09/724,869
	Filing Date	November 28, 2000
	First Named Inventor	Juha Punnonen
	Group Art Unit	1639
	Examiner Name	Teresa Wessendorf
	Attorney Docket Number	0155.130US


U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			
	1	6,368,861		Crameri et al.	04-23-2002	
	2	6,406,855		Patten et al.	06-18-2002	
	3	6,613,514		Patten et al.	09-02-2003	

FOREIGN PATENT DOCUMENTS								
Exami ner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Office	Number	Kind Code (if known)				

*duplicate  
see IDS of 6/14/07*

Examiner Signature		Initial Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A-B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	Complete if Known	
	Application Number	09/724,869
	Filing Date	November 28, 2000
	First Named Inventor	Juha Punnonen
	Group Art Unit	1639
	Examiner Name	Teresa Wessendorf
	Attorney Docket Number	0155.130US

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
	1	6,376,246		Cramer et al.	04-09-2002	

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office	Number	Kind Code (if known)			
	2	WO	91/19818	A1	Affymax Technologies N.V.	12-26-1991	
	3	WO	92/01047	A1	Cambridge Antibody Technology Limited	01-23-1992	
	4	WO	92/18619	A1	The Scripps Research Institute	10-29-1992	
	5	WO	94/01567	A1	Unilever PLC	01-20-1994	
	6	WO	94/18330	A1	Unilever PLC	08-18-1994	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	7	Aggarwal & Gutterman eds., HUMAN CYTOKINES: HANDBOOK FOR BASIC AND CLINICAL RESEARCH, Vol. II (1996) (Table of Contents for Vols. 1 & II)	
	8	Alcami et al., "A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection," <i>Cell</i> 71(1):153-67 (1992)	
	9	Apostolopoulos et al., "Breast cancer immunotherapy: Current status and future prospects," <i>Immunol. and Cell. Biol.</i> 74:457-64 (1996)	
	10	Atamas et al., "An alternative splice variant of human IL-4, IL-4 delta 2, inhibits IL-4-stimulated T cell proliferation," <i>J. Immunol.</i> 156(2):435-41 (1996)	
	11	Aversa et al., "SLAM and its role in T cell activation and Th cell responses." <i>Immunol. Cell Biol.</i> 75(2):202-5 (1997)	
	12	Bach et al., "The IFN gamma receptor: a paradigm for cytokine receptor signaling," <i>Annu. Rev. Immunol.</i> 15:563-91 (1997)	
	13	Baggiolini et al., "Human Cytokines: An Update," <i>Annu. Rev. Immunol.</i> 15:675-705 (1997)	
	14	Balbas et al., "Design and Construction of Expression Plasmid Vectors in Escherichia coli," in <i>METHODS IN ENZYMOLOGY: GENE EXPRESSION TECHNOLOGY</i> 185:14-37 (David V. Goeddel ed., Acad. Press, Inc., 1990)	
	15	Basham et al., "Synergistic antitumor activity with IFN and monoclonal anti-idiotypic for murine B cell lymphoma. Mechanism of action," <i>J. Immunol.</i> 141(8):2855-60 (1988)	
	16	Beck et al., "Analysis of Multiple Plasmodium falciparum Infections in Tanzanian Children during the Phase II Trial of Malaria Vaccine SPf66," <i>J. Inf. Disease</i> 175:921-26 (1997)	



17	Becket <i>et al.</i> , "Characterization of a Prostate Carcinoma Mucin-Like Antigen (PMA)," <i>Int. J. Cancer</i> 62:703-10 (1995)	
18	Bramson <i>et al.</i> , "Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: in vitro and in vivo production of biologically active interleukin-12," <i>Hum. Gene Ther.</i> 7(3):333-42 (1996)	
19	Brusselle <i>et al.</i> , "Role of IFN- $\gamma$ in the Inhibition of Allergic Airway Inflammation Caused by IL-12," <i>Am. J. Respir. Cell Mol. Biol.</i> 17:767-71 (1997)	
20	Censini <i>et al.</i> , "cag, a pathogenicity island of <i>Helicobacter pylori</i> , encodes type I-specific and disease-associated virulence factors," <i>PNAS</i> 93:14648-53 (1996)	
21	Chen <i>et al.</i> , "Discontinuous epitopes of hepatitis B surface antigen derived from a filamentous phage peptide library," <i>PNAS USA</i> 93(5):1997-2001 (1996)	
22	Chow <i>et al.</i> , "Improvement of Hepatitis B Virus DNA Vaccines by Plasmids Coexpressing Hepatitis B Surface Antigen and Interleukin-2," <i>J. Virol.</i> 71(1):169-78 (1997)	
23	Ciernik <i>et al.</i> , "Induction of Cytotoxic T Lymphocytes and Antitumor Immunity with DNA Vaccines Expressing Single T Cell Epitopes," <i>J. Immunol.</i> 156:2369-75 (1996)	
24	Cohen <i>et al.</i> , "Host factors in the pathogenesis of HIV disease," <i>Immunol. Rev.</i> 159:31-48 (1997)	
25	Cortese <i>et al.</i> , "Selection of biologically active peptides by phage display of random peptide libraries," <i>Curr. Opin. Biotechnol.</i> 7(6):616-21 (1996)	
26	Curtis <i>et al.</i> , "Recombinant Soluble Interleukin-11 (IL-11) Receptor alpha Chain Can Act as an IL-11 Antagonist," <i>Blood</i> 90(11):4403-12 (1997)	
27	Cwirla <i>et al.</i> , "Peptide Agonist of the Thrombopoietin Receptor as Potent as the Natural Cytokine," <i>Science</i> 276:1696-9 (1997)	
28	Dagan <i>et al.</i> , "High level expression and production of recombinant human interleukin analogs," <i>Protein Expr. Purif.</i> 3(4):290-4 (1992)	
29	Devos <i>et al.</i> , "Interleukin-5 and its receptor: a drug target for eosinophilia associated with chronic allergic disease," <i>J. Leukoc. Biol.</i> 57(6):813-19 (1995)	
30	De Vries <i>et al.</i> , "Novel fundamental approaches to intervening in IgE-mediated allergic diseases," <i>J. Invest. Dermatol.</i> 102(2):141-4 (1994)	
31	De Vries <i>et al.</i> , <i>Interleukin-4 and Interleukin-13</i> , Chap. 8, in <i>CYTOKINE REGULATION OF HUMORAL IMMUNITY: BASIC AND CLINICAL ASPECTS</i> 195-215 (C. M. Snapper, West Sussex, UK, John Wiley and Sons, 1996)	
32	De Vries <i>et al.</i> , "Modulation of the human IgE response," <i>Eur. Respir. J. Suppl.</i> 22:58s-62s (1996)	
33	De Waal Malefyt <i>et al.</i> , "A Novel Cytokine Belonging to the IL-10 Gene Family Affects Human Monocytes and T Cells," Abstract, 13th European Immunology Meeting, Amsterdam, Netherlands, June 1997, <i>Immunol. Letters</i> 56(1):211 (May 1997)	
34	Donnelly <i>et al.</i> , "DNA Vaccines," <i>Annu. Rev. Immunol.</i> 15:617-48 (1997)	
35	Dudler <i>et al.</i> , "A Link Between Catalytic Activity, IgE-Independent Mast Cell Activation and Allergenicity of Bee Venom Phospholipase A <sub>2</sub> ," <i>J. Immunol.</i> 155(5):2605-13 (1995)	
36	Eckhart <i>et al.</i> , "Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus," <i>J. Gen. Virol.</i> 77 (9):2001-8 (1996)	
Examiner Signature		Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

37	Fomsgaard <i>et al.</i> , "Improved humoral and cellular immune response against the gp120 V3 loop of HIV-1 following genetic immunization with a chimeric DNA vaccine encoding the V3 inserted in the hepatitis B surface antigen," <i>Scand. J. Immunol.</i> 47(4):289-95 (1998)	
38	Foy <i>et al.</i> , "Immune regulation by CD40 and its ligand GP39," <i>Annu. Rev. Immunol.</i> 14:591-617 (1996)	
39	Fromm <i>et al.</i> , "Expression of genes transferred into monocot and dicot plant cells by electroporation," <i>PNAS USA</i> 82(17):5824-28 (1985)	
40	Gauchat <i>et al.</i> , "Regulation of human IgE synthesis: the role of CD4+ and CD8+ T-cells and the inhibitory effects of interferon-alpha," <i>Eur. Respir. J. Suppl.</i> 13:31s-38s (1991)	
41	Goff <i>et al.</i> , "Laboratory Methods: Efficient Saturation Mutagenesis of a Pentapeptide Coding Sequence Using Mixed Oligonucleotides," <i>DNA</i> 6(4):381-388 (1987)	
42	Greenfeder <i>et al.</i> , "Insertion of a Structural Domain of Interleukin (IL)-1B Confers Agonist Activity to the IL-1 Receptor Antagonist," <i>J. Biol. Chem.</i> 270/22460-6 (1995)	
43	Grewal <i>et al.</i> , "The CD40-CD154 system in anti-infective host defense," <i>Curr. Opin. Immunol.</i> 9(4):491-7 (1997)	
44	Grunig <i>et al.</i> , "Interleukin-10 is a natural suppressor of cytokine production and inflammation in a murine model of allergic bronchopulmonary aspergillosis," <i>J. Exp. Med.</i> 185(6):1089-99 (1997)	
45	Hannum <i>et al.</i> , "Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor," <i>Nature</i> 343:336-40 (1990)	
46	Hathcock <i>et al.</i> , "Comparative Analysis of B7-1 and B7-2 Costimulatory Ligands: Expression and Function," <i>J. Exptl. Med.</i> 180:631-40 (1994)	
47	Herz <i>et al.</i> , "Molecular approaches to receptors as targets for drug discovery," <i>J. Recept. Signal Transduct. Res.</i> 17(5):671-776 (1997)	
48	Herzenberg <i>et al.</i> eds., WEIR'S HANDBOOK OF EXPERIMENTAL IMMUNOLOGY (5 <sup>th</sup> ed. 1996) (index and first pages of Chaps. 220, 226, 227)	
49	Hess <i>et al.</i> , "Superior efficacy of secreted over somatic antigen display in recombinant <i>Salmonella</i> vaccine induced protection against listeriosis," <i>PNAS</i> 93:1458-63 (1996)	
50	Hill <i>et al.</i> , "Mutagenesis with Degenerate Oligonucleotides: An Efficient Method for Saturating a Defined DNA Region with Base Pair Substitutions," in <i>METHODS IN ENZYMOLOGY: RECOMBINANT DNA</i> 155:558-568 (Ray Wu ed., Acad. Press, Inc., 1987)	
51	Horuk, "Molecular properties of the chemokine receptor family," <i>TIPS</i> 15:159-165 (1994)	
52	Horwitz <i>et al.</i> , "Saturation Mutagenesis Using Mixed Oligonucleotides and M13 Templates Containing Uracil," in <i>METHODS IN ENZYMOLOGY: GENE EXPRESSION TECHNOLOGY</i> 185:599-611 (David V. Goeddel ed., Acad. Press, Inc. 1990)	
53	Ihle <i>et al.</i> , "Signaling through the hematopoietic cytokine receptors," <i>Annu. Rev. Immunol.</i> 13:369-98 (1995)	
54	Kaufman, "Vectors Used for Expression in Mammalian Cells," in <i>METHODS IN ENZYMOLOGY: GENE EXPRESSION TECHNOLOGY</i> 185:487-511 (David V. Goeddel ed., Acad. Press, Inc., 1990)	
55	Kay <i>et al.</i> , eds., <i>PHAGE DISPLAY OF PEPTIDES AND PROTEINS: A LABORATORY MANUAL</i> (Acad. Press, Inc., 1996) (first page of Chap. 5)	
56	Krieger <i>et al.</i> , "Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP)," <i>Annu. Rev. Biochem.</i> 63:601-	
Examiner Signature		Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	37 (1994)	
57	Kroemer <i>et al.</i> , "Immunoregulation by cytokines," <i>Crit. Rev. Immunol.</i> 13(2):163-91 (1993)	
58	Laberge <i>et al.</i> , "Secretion of IL-16 (Lymphocyte Chemoattractant Factor) from Serotonin-Stimulated CD8 <sup>+</sup> T Cells In Vivo," <i>J. Immunol.</i> 156(1):370-5 (1996)	
59	Le Borgne <i>et al.</i> , "In Vivo Induction of Specific Cytotoxic T Lymphocytes in Mice and Rhesus Macaques Immunized with DNA Vector Encoding an HIV Epitope Fused with Hepatitis B Surface Antigen," <i>Virology</i> 240:304-15 (1998)	
60	Le Grice, "Regulated Promoter for High-Level Expression of Heterologous Genes for <i>Bacillus subtilis</i> ," in METHODS IN ENZYMOLOGY: GENE EXPRESSION TECHNOLOGY 185:201-15 (David V. Goeddel ed., Acad. Press, Inc., 1990)	
61	Levinson, "Expression of Heterologous Genes in Mammalian Cells," in METHODS IN ENZYMOLOGY: GENE EXPRESSION TECHNOLOGY 185:485-87 (David V. Goeddel ed., Acad. Press, Inc., 1990)	
62	Livnah <i>et al.</i> , "Functional Mimicry of a Protein Hormone by a Peptide Agonist: The EPO Receptor Complex at 2.8," <i>Science</i> 273:464-71 (1996)	
63	Ma <i>et al.</i> , "Antibody production and engineering in plants," <i>Ann. NY Acad. Sci.</i> 792:72-81 (1996)	
64	Mattion <i>et al.</i> , "Characterization of recombinant polioviruses expressing regions of rotavirus VP4, hepatitis B surface antigen, and herpes simplex virus type 2 glycoprotein D," <i>J. Virol.</i> 69:5132-37 (1995)	
65	McLafferty <i>et al.</i> , "M13 bacteriophage displaying disulfide-constrained microproteins," <i>Gene</i> 128(1):29-36 (1993)	
66	Miele, "Plants as bioreactors for biopharmaceuticals: regulatory considerations," <i>Trends Biotechnol.</i> 15(2):45-50 (1997)	
67	Mosmann <i>et al.</i> , "Heterogeneity of Cytokine Secretion Patterns and Functions of Helper T cells," <i>Adv. Immunol.</i> 46:111-147 (1989)	
68	Murray <i>et al.</i> , "Saturation mutagenesis of a major histocompatibility complex protein domain: Identification of a single conserved amino acid important for allorecognition," <i>PNAS USA</i> 85:3535-39 (1988)	
69	Noguchi <i>et al.</i> , "IgE responsiveness to <i>Dermatophagoides farinae</i> in young asthmatic children: IgE binding study using recombinant allergens of Der f1, Der f2 and mutant proteins of Der f2," <i>Int. Arch. Allergy Immunol.</i> 110(4):380-7 (1996)	
70	Ostermeier <i>et al.</i> , "A combinatorial approach to hybrid enzymes independent of DNA homology," <i>Nature</i> 19:1205-09 (1999)	
71	Ostermeier <i>et al.</i> , "Combinatorial protein engineering by incremental truncation," <i>PNAS USA</i> 96:3562-67 (1999)	
72	Parronchi <i>et al.</i> , "IL-4 and IFN (alpha and gamma) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones," <i>J. Immunol.</i> 149(9):2977-83 (1992)	
73	Paul, <i>The Immune System: An Introduction</i> , Chap. 1, pp. 1-20 in FUNDAMENTAL IMMUNOLOGY (W. E. Paul. New York, Raven Press, 1993)	
74	Porcelli, "The CD1 family: a third lineage of antigen-presenting molecules," <i>Adv. Immunol.</i> 59:1-98 (1995)	
Examiner Signature		Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

75	Pumpens <i>et al.</i> , "Hepatitis B virus core particles as epitope carriers," <i>Intervirology</i> 38(1-2):63-74 (1995)
76	Quarantino <i>et al.</i> , "Similar antigenic surfaces, rather than sequence homology dictate T-cell epitope molecular mimicry," <i>PNAS USA</i> 92:10398-402 (1995)
77	Randhawa <i>et al.</i> , "In vitro culture of B-lymphocytes derived from Epstein-Barr-virus-associated posttransplant lymphoproliferative disease: cytokine production and effect of interferon-alpha," <i>In Vitro Cell Dev. Biol. Anim.</i> 33(10):803-08 (1997)
78	Sambrook <i>et al.</i> , MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Laboratory Press, New York (2d ed. 1989), Vol. I, pp. 1.53-1.59
79	Sambrook <i>et al.</i> , MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Laboratory Press, New York (2d ed. 1989), Vol. II, pp. 15.51-15.113
80	Schrijver <i>et al.</i> , "Comparison of DNA application methods to reduce BRSV shedding in cattle," <i>Vaccine</i> 16(2-3):130-4 (1998)
81	Simmons <i>et al.</i> , "Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist," <i>Science</i> 276:276-9 (1997)
82	Stern <i>et al.</i> , Chap. 4, <i>Interleukin-12</i> , in HUMAN CYTOKINES: HANDBOOK FOR BASIC AND CLINICAL RESEARCH 74-96 (Aggarwal & Gutterman eds., 1996)
83	Tan <i>et al.</i> , "Characterization of IL-10 Receptors on Human and Mouse Cells," <i>J. Biol. Chem.</i> 268(28):21053-59 (1993)
84	Thomas <i>et al.</i> , "Potent interleukin 3 receptor agonist with selectively enhanced hematopoietic activity relative to recombinant human interleukin 3," <i>PNAS USA</i> 92:3779-83 (1995)
85	Tuite, "Strategies for the genetic manipulation of <i>Saccharomyces cerevisiae</i> ," <i>Crit. Rev. Biotechnol.</i> 12(1-2):157-88 (1992)
86	Udagawa <i>et al.</i> , "Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation," <i>J. Exp. Med.</i> 185(6):1005-12 (1997)
87	Ulrich <i>et al.</i> , "Chimeric HBV core particles carrying a defined segment of Puumala hantavirus nucleocapsid protein evoke protective immunity in an animal model," <i>Vaccine</i> 16(2-3):272-80 (1998)
88	Villbrandt <i>et al.</i> , "Investigations of the thermostability and function of truncated <i>Thermus aquaticus</i> DNA polymerase fragments," <i>Protein Eng'g</i> 10(11):1281-88 (1997)
89	Weiner <i>et al.</i> , "Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization," <i>PNAS USA</i> 94:10833-7 (1997)
90	Yao <i>et al.</i> , "Human IL-17: A Novel Cytokine Derived from T Cells," <i>J. Immunol.</i> 155(12):5483-86 (1995)
91	York <i>et al.</i> , "Antigen processing and presentation by the class I major histocompatibility complex," <i>Annu. Rev. Immunol.</i> 14:369-96 (1996)
92	Yoshie <i>et al.</i> , "Novel lymphocyte-specific CC chemokines and their receptors," <i>J. Leukocyte Biol.</i> 62(5):634-44 (1997)
93	Zaremba <i>et al.</i> , "Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen," <i>Cancer Res.</i> 57(20):4570-77 (1997)

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.